Boehringer Ingelheim and Pharmaxis Halt the Development of BI 1467335 for Diabetic Retinopathy

 Boehringer Ingelheim and Pharmaxis Halt the Development of BI 1467335 for Diabetic Retinopathy

Boehringer Ingelheim and Pharmaxis Halt the Development of BI 1467335 for Diabetic Retinopathy

Shots:

  • The companies discontinue the P-IIa study assessing BI 1467335 vs PBO in 79 patients with moderately severe to severe NPDR without CIDME for 12wks. treatment period with an additional 12wks. follow-up period afterward. The study met its 1EPs in ocular safety with the treatment being well-tolerated
  • The discontinuation is due to a lack of a clear efficacy signal and risk of dose-dependent drug interactions of the compound in NPDR patients identified in another P-I study. Additionally, Boehringer Ingelheim has terminated its 2015 agreement with Pharmaxis with 90 days notice period
  • Boehringer Ingelheim will deploy its expertise in multiple therapeutic areas and will advance  its portfolio of next-generation retinal therapy approaches while Pharmaxis will continue its development of amine oxidase inhibitors with a P-II study in myelofibrosis, commencing later this year

Click here ­to­ read full press release/ article | Ref: Boehringer Ingelheim | Image: Barnet Dulaney Perkins Eye Center

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post